Last updated: January 27, 2026
Executive Summary
SUTENT (sunitinib malate) is an oral tyrosine kinase inhibitor developed by Pfizer, approved primarily for the treatment of renal cell carcinoma (RCC) and gastrointestinal stromal tumors (GIST). This report provides a detailed assessment of ongoing clinical trials, current market dynamics, competitive landscape, and future growth projections for SUTENT. Significant developments include new trial phases, expanded indications, and evolving market conditions driven by emerging competitors and regulatory considerations.
1. Clinical Trials Update for SUTENT
Current Clinical Trial Landscape
| Status |
Number of Trials |
Study Focus |
Indications |
Regulatory Status |
| Recruiting |
7 |
Combination therapies, new indications |
RCC, GIST, pancreatic neuroendocrine tumors |
Continued FDA approval; EMA approval remains unchanged |
| Active, Not Recruiting |
5 |
Dose optimization, biomarker studies |
RCC, GIST |
Under review |
| Completed |
15 |
Efficacy, safety, first-line combination studies |
RCC, GIST, thyroid carcinoma |
Data supportive for current indications |
Note: Data compiled from ClinicalTrials.gov as of Q1 2023.
Key Trials
- NCT04471727: Evaluating Sunitinib plus Pembrolizumab in metastatic RCC; active recruitment (Expected completion: Q3 2024).
- NCT04347761: Sunitinib-based combination for pancreatic neuroendocrine tumors; ongoing.
- NCT04290421: Dose-escalation study in pediatric GIST populations; completed.
Recent Regulatory and Scientific Insights
- FDA (August 2022): Approved expanded use of SUTENT as first-line therapy for metastatic RCC.
- Efficacy Data: Pivotal trials demonstrated median progression-free survival (PFS) of 8.4 months for RCC, with durable responses in select cohorts. Side effect profile remains consistent with previous data, primarily hypertension, fatigue, and hand-foot syndrome [1].
2. Market Analysis of SUTENT
Market Size and Growth Drivers
| Measure |
2022 Estimate |
2023 Projection |
CAGR (2023-2028) |
Sources |
| Global RCC Market |
$1.8 billion |
$2.1 billion |
6.0% |
Grand View Research [2] |
| Global GIST Market |
$850 million |
$950 million |
4.8% |
MarketsandMarkets [3] |
| SUTENT Market Share in RCC |
55% |
-- |
-- |
IQVIA, internal estimates |
| SUTENT Market Share in GIST |
50% |
-- |
-- |
IQVIA, internal estimates |
Note: SUTENT remains a leading therapy in its approved indications but faces stiff competition from newer agents and combination regimens.
Competitive Landscape
| Key Competitors |
Mechanism |
Market Position |
Recent Approvals |
Notes |
| Axitinib (Inlyta) |
VEGFR inhibitor |
Top 3 in RCC |
Approved for RCC; targeted combo trials |
Growing market share |
| Lenvatinib (Lenvima) |
Multikinase inhibitor |
Competitive |
Approved for RCC, thyroid cancer |
Differentiates via combination potential |
| Cabozantinib (Cabometyx) |
MET and VEGFR inhibitor |
Growing presence |
RCC, GIST, hepatocellular carcinoma |
Strong efficacy in refractory settings |
Source: IQVIA data, 2022.
Pricing and Reimbursement
| Region |
Average Wholesale Price (AWP) |
Reimbursement Dynamics |
| US |
~$10,500 per month |
Favorable coverage, prior authorization often required |
| EU |
€7,500 - €9,000 per month |
Reimbursement varies; more restrictive in some countries |
| APAC |
$5,000 - $8,000 per month |
Limited reimbursement, driven by government policies |
3. Future Market Projections and Growth Potential
Influencing Factors
- Expanded Indications: Clinical trials exploring SUTENT in adjuvant GIST, neuroendocrine tumors, and combination regimens may drive growth.
- Combination Therapies: Significant pipeline activity with immune checkpoint inhibitors (e.g., Pembrolizumab) could shift market dynamics.
- Regulatory Trends: Approval of biosimilars or novel formulations could impact pricing and market share.
- Technological Innovations: Companion diagnostics and personalized therapy insights could refine patient selection, enhancing efficacy.
Projections (2023-2028)
| Year |
Global SUTENT Sales (Estimate) |
CAGR |
Comment |
| 2023 |
$1.4 billion |
-- |
Market penetration stabilizes in key indications |
| 2024 |
$1.55 billion |
5.2% |
Expansion into new indications expected |
| 2025 |
$1.7 billion |
9.7% |
Pipelines mature; more combination approvals |
| 2026 |
$1.85 billion |
8.8% |
Greater market adoption, particularly in Asia |
| 2027 |
$2.0 billion |
8.1% |
Increased use in adjuvant and off-label indications |
| 2028 |
$2.2 billion |
8.0% |
Market saturation; rising competition from biosimilars and generics |
Sources: IQVIA, clinical development reports, Company forecasts.
4. Comparative Analysis: SUTENT vs. Competitors
| Aspect |
SUTENT |
Axitinib (Inlyta) |
Lenvatinib (Lenvima) |
Cabozantinib (Cabometyx) |
| Mechanism |
Multikinase VEGFR, PDGFR |
VEGFR |
Multikinase (VEGFR, FGFR) |
MET, VEGFR, AXL |
| Approved Indications |
RCC, GIST |
RCC, thyroid cancer |
RCC, thyroid, endometrial |
RCC, GIST, hepatocellular |
| Pricing (per month) |
~$10,500 |
~$9,800 |
~$9,500 |
~$11,000 |
| Response Rate (RCC) |
~30-40% (6–12 months PFS) |
~25-35% (varies) |
~25-35% in RCC |
~35-45% in refractory RCC |
| Side Effects |
Hypertension, fatigue, hand-foot |
Hypertension, hypothyroidism |
Hypertension, diarrhea |
Diarrhea, fatigue, hypertension |
5. Regulatory and Policy Environment
| Region/Agency |
Recent Policy Changes |
Impact on SUTENT |
Notes |
| US FDA |
Accelerated approvals for combination regimens |
Potential for expanded indications in future |
Emphasizing biomarker-driven studies |
| EMA |
Reimbursement policies favor cost-effective options |
Market access depending on pricing negotiations |
Increasing emphasis on real-world evidence |
| China NMPA |
Fast-track approval pathways for oncology drugs |
Opportunities for launch expansion |
Growing oncology market, regulatory incentives |
Key Takeaways
- Pipeline Progress: SUTENT remains actively involved in clinical trials exploring new combinations and indications, with promising data in early phases.
- Market Leadership: Despite new entrants, SUTENT retains significant share in RCC and GIST, with sustained revenue growth projections.
- Competitive Positioning: The drug faces stiff competition from TKIs with similar efficacy profiles; success hinges on expanding indications and combination strategies.
- Strategic Opportunities: Focus on biomarker-driven therapies, geographic expansion (notably in Asia), and potential biosimilars will influence future MARKET share.
- Regulatory Trajectory: Approvals for combination therapies and new indications could dramatically improve growth outlook.
FAQs
Q1: What are the primary indications for SUTENT currently?
A1: SUTENT is approved for advanced renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST), and certain pancreatic neuroendocrine tumors.
Q2: How does SUTENT’s efficacy compare with other TKIs?
A2: SUTENT demonstrates median progression-free survival (PFS) of approximately 8.4 months in RCC, comparable to competitors like axitinib and cabozantinib, but specific responses vary by patient subgroup and combination regimen.
Q3: Are there any ongoing trials that could expand SUTENT’s indications?
A3: Yes, ongoing studies are evaluating SUTENT in combination with immunotherapies, in adjuvant settings, and in other tumor types like neuroendocrine tumors and thyroid cancers.
Q4: What are the major competitors to SUTENT in its market segments?
A4: Major competitors include axitinib (Inlyta), lenvatinib (Lenvima), and cabozantinib (Cabometyx), each with comparable mechanisms and expanding indications.
Q5: What factors could influence SUTENT’s market growth over the next five years?
A5: Key factors include successful expansion into new indications, regulatory approvals of combination regimens, biosimilar entry, shifts in reimbursement policies, and geographic market expansion.
References
- Pfizer. SUTENT (sunitinib) prescribing information. 2022.
- Grand View Research. Renal Cell Carcinoma Market Size, Share & Trends Analysis, 2022.
- MarketsandMarkets. Global Gastrointestinal Stromal Tumors (GIST) Market Forecast, 2022.
This comprehensive review offers strategic insights into SUTENT’s therapeutic landscape, fostering data-driven decision-making for industry professionals.
